EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Hilal Karakas, Selver Isık, Murat Günaltılı, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu und 6 weitere

Clinical and Translational Oncology · 15.01.2025 · 27 (7) · 3110-3120

DOI: 10.1007/s12094-024-03813-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 15.01.2025. Verfasst von Hatice Bolek und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara University School of Medicine, 06590, Ankara, Türkiye. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Blood Glucose. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Social Science University of Ankara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy.

Methods

A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 9 /L). We categorized patients into two categories based on their median GLR level.

Results

The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7–17.4) compared to 7.79 months (95% CI 6.6–9.0) in the GLR-high group ( p < 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12–1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9–46.0) compared to 24.15 months (95% CI 18.0–30.2) in the GLR-high group ( p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12–1.86; p = 0.004).

Conclusion

The GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsProtein Kinase InhibitorsBlood GlucoseLymphocytesHumansMaleFemaleRetrospective StudiesMiddle AgedPrognosisAgedTurkeyAdultLymphocyte CountProgression-Free SurvivalAged, 80 and overSurvival RateTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

GLRGlucose-to-lymphocyte ratioRenal cell carcinomaTyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsBlood GlucoseTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Ankara University School of Medicine, 06590, Ankara, Türkiye.
  • Ankara University Cancer Institute, Ankara, Türkiye.
  • Department of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
  • Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
  • Department of Medical Oncology, Ege University School of Medicine, Izmir, Türkiye.
  • Department of Medical Oncology, Bilkent City Hospital, Ankara, Türkiye.

Förderung

  • Social Science University of Ankara

Zitieren

APA

Bolek, H., Kuzu, O. F., Sertesen Camoz, E., Sim, S., Sekmek, S., Karakas, H., Isık, S., Günaltılı, M., Akkus, A. F., Tural, D., Arslan, C., Goksu, S. S., Sever, O. N., Karadurmus, N., Karacin, C., Sendur, M. A. N., Yekedüz, E., & Urun, Y. (2025). Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC). Clinical and Translational Oncology, 27(7), 3110-3120. https://doi.org/10.1007/s12094-024-03813-w

Vancouver

Bolek H, Kuzu OF, Sertesen Camoz E, Sim S, Sekmek S, Karakas H, et al. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC). Clinical and Translational Oncology. 2025;27(7):3110-3120. doi:10.1007/s12094-024-03813-w

BibTeX
@article{Bolek2025,
  author = {Bolek, Hatice and Kuzu, Omer Faruk and Sertesen Camoz, Elif and Sim, Saadet and Sekmek, Serhat and Karakas, Hilal and Isık, Selver and Günaltılı, Murat and Akkus, Aysun Fatma and Tural, Deniz and Arslan, Cagatay and Goksu, Sema Sezin and Sever, Ozlem Nuray and Karadurmus, Nuri and Karacin, Cengiz and Sendur, Mehmet Ali Nahit and Yekedüz, Emre and Urun, Yuksel},
  title = {Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)},
  journal = {Clinical and Translational Oncology},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3110--3120},
  doi = {10.1007/s12094-024-03813-w}
}
Kostenlos starten →